You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

 

Online download statistics by month:

Online download statistics by month: January 2020 to March 2024

AbstractFullPdf
Jan 202013130
Feb 202047470
Mar 202063632
Apr 2020828213
May 202011511527
Jun 2020575723
Jul 2020494911
Aug 2020595921
Sep 202014014043
Oct 202012612665
Nov 2020757552
Dec 2020636347
Jan 2021575749
Feb 2021545450
Mar 2021585866
Apr 2021696961
May 2021676771
Jun 2021909071
Jul 2021707058
Aug 2021626249
Sep 202110410464
Oct 202110810891
Nov 2021989880
Dec 202114414783
Jan 202211712673
Feb 2022888957
Mar 202214414861
Apr 202213513761
May 2022889556
Jun 20229610561
Jul 2022929753
Aug 20229610252
Sep 20229710157
Oct 2022808055
Nov 202216416683
Dec 202212412661
Jan 202310310646
Feb 202312012167
Mar 2023788049
Apr 2023949756
May 2023838350
Jun 2023788029
Jul 2023959849
Aug 20239910142
Sep 202315315535
Oct 202326826842
Nov 202348148237
Dec 2023757642
Jan 2024606035
Feb 202410511033
Mar 202446446590
Total554756272529